Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

  • Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up visit (FU). Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon p<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.

Export metadata

Metadaten
Author:Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia DietzORCiDGND, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph SarrazinGND, Grith Lykke Sørensen, Barbara Sitek, Thilo Bracht
URN:urn:nbn:de:hebis:30:3-484281
DOI:https://doi.org/10.3350/cmh.2018.0029
ISSN:2287-285X
ISSN:2287-2728
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/30449076
Parent Title (English):Clinical and molecular hepatology
Publisher:Assoc.
Place of publication:Seoul
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/11/19
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2018/12/04
Tag:Antiviral agents; Biomarkers; Extracellular matrix proteins; Hepatitis C, Chronic; Liver cirrhosis
Volume:24
Issue:cmh.2018.0029
Page Number:10
First Page:1
Last Page:10
Note:
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
HeBIS-PPN:440093430
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell 3.0